| 产品名称： |
Regorafenib (BAY 73-4506) |
| 中文别名： |
瑞格菲尼;瑞格非尼;瑞戈非尼;4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺;4-[4-({[4-氯-3-(三氟甲基)苯基]氨甲酰基}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺;Regorafenib（BAY73-4506） 抑制剂;科研实验瑞格非尼;瑞戈非尼-13C-D3;瑞格非尼靶向药;瑞格非尼标准品;瑞格非尼固体状;瑞格非尼无水物;瑞格非尼杂质;瑞格菲尼杂质;五氟丙酸钠盐;医药级瑞格非尼;阿尔法育亨宾;育亨宾碱;瑞格菲尼无水物;瑞格菲尼及中间体;BAY 73-4506/ 瑞格非尼/ 4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺;REGORAFENIB 瑞格非尼;4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基 }羰基)氨基]苯氧基}-N-甲基吡啶-2-甲酰胺;4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨;瑞格非尼 1KG |
| 英文名称： |
Regorafenib |
| 英文别名： |
4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide;BAY 73-4506;4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;BAY 73-4506(Regorafenib);4-[4-({[4-chioro-3-(trifluoroMethyl)phenyl]carbaMoyl}aMino)-3-fluorophenoxy]-pyridine-2-carboxylic acid MethylaMide;Regorafenib (BAY 73-4506);4-[4-[[[[4-Chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]-3-fluorophenoxy]-N-Methyl-2-pyridinecarboxaMide;4-[4-[N'-(4-Chloro-3-trifluoroMethylphenyl)ureido]-3- fluorophenoxy]pyridine-2-carboxylic Acid MethylaMide;4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;Regorafenib;Regorafenib（BAY73-4506）;Regorafenib hydrate;BAY734506;FREE BASE;4-(4-(3-(4-chloro-3-(trifluoroMethyl)phenyl)ureido)-3-fluorophenoxy)-N-MethylpicolinaMide;REGORAFENIB BAY 73-4506 BAYER HEALTHCARE (SEE ALSO COLORECTAL, LUNG, STOMACH) PHASE II(REGORAFENIB) PHARMACEUTICALS (888) 842-2937WAYNE, NJ |
| 品牌： |
PERFEMIKER |
| CAS号： |
755037-03-7 |
| 分子式： |
C₂₁H₁₅CLF₄N₄O₃ |
| 分子量： |
482.82 |
| 纯度： |
99% |
| 详细描述： |
Regorafenib (BAY 73-4506)是多靶点抑制剂，对VEGFR1，VEGFR2，VEGFR3，PDGFRβ，Kit，RET和Raf-1的IC50分别为13 nM，4.2 nM，46 nM |
沪公网安备31011402010658号 
